Anas Hamad: Thrombosis as Overlooked Clinical Challenge in APL
Anas Hamad, Deputy Chief of Drug Supply Department, Head of Pharmacy Research Center, Corporate Pharmacy Executive Office at Hamad Medical Corporation, Lead of Health Technology Assessment and Innovation Regulation National Program at Ministry of Public Health – Qatar, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Sage Journals, adding:
“I am pleased to share our recently published study in clinical and applied Thrombosis/Hemostasis Journal by Sage: ‘Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia — A Single-Center Experience from the GCC Region.’
APL is often recognized for its bleeding risk, but our study highlights another important and sometimes underrecognized clinical challenge: thrombosis.
In this work from the National Center for Cancer Care and Research in Qatar, we reviewed 75 consecutive patients with newly diagnosed APL treated between 2015 and 2024.
We found that 14.7 percent developed thrombosis, with most events occurring during active therapy.
Importantly, this study reinforces that managing APL requires careful attention to both sides of the coagulation spectrum: bleeding and thrombosis.
This balance is particularly critical during induction and early consolidation, where individualized thrombo-hemorrhagic assessment and multidisciplinary decision-making are essential.
Grateful to all the authors team for their great efforts and valuable contributions to this publication.”
Title: Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia — A Single-Center Experience from the GCC Region
Authors: Shehab F. Mohamed, Rafal AlShebly, Hawraa Shawaylia, Anil Elahie, Rola Ghasoub, Dina Soliman, Deen Mudawi, Mohammed Abdulgayoom, Abdulrahman F. Al-Mashdali, Marrita Rabadi, Hesham El-Sabah, Anas Hamad, Mohamed Yassin, Honar Cherif
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 8, 2026, 11:33Ifeanyichukwu Ifechidere: Haemophilia A and B – From First Diagnosis to the Era of Gene Therapy
-
Jul 8, 2026, 10:29Bringing Hemophilia Care Closer to Communities in Togo – WFH
-
Jul 8, 2026, 10:12Natasha Jolakoski: Completing Advanced Training in Thrombosis and Hemostasis
-
Jul 8, 2026, 09:58Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism